相关实验视频

Updated: Jan 13, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

一个模块化的mRNA平台,用于可编程诱导瘤特异性免疫细胞死亡

Songtao Dong¹, Shannon N Tsai¹, Yue Xu¹

¹Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.

Nature nanotechnology

|October 30, 2025

概括

一个新的纳米医学平台,TITUR,增强了传递 RNA (mRNA) 到瘤的传递. 这种方法通过减少副作用和增强抗瘤免疫反应来改善癌症免疫疗法.

科学领域:

在瘤学瘤学.
纳米医学是一种纳米医学.
免疫治疗是一种免疫疗法.

背景情况:

使者RNA (mRNA) 疗法在瘤学中表现有前途,但面临着系统性脱效应和免疫抑制瘤微环境的挑战.
目前的输送方法往往导致毒性和在固体瘤中的有效性有限.

研究的目的:

开发一个瘤可定制的mRNA纳米医学平台 (TITUR),以增强瘤选择性传递和表达.
调查TITUR诱导免疫细胞死亡和克服瘤免疫抑制的潜力.

主要方法:

TITUR平台整合了瘤可定制的电离性脂质 (TI) 和瘤特异性的未翻译区域 (TUR).
在黑色素瘤和三阴性乳腺癌的小鼠模型中,输入编码4HB的mRNA,一种免疫细胞死亡诱导蛋白质.
结合疗法与免疫检查点抑制剂.

主要成果:

TITUR实现了4HB的精确内表达,减轻了全身毒性.
4HB的输送诱导了瘤特异性免疫细胞死亡,重塑了瘤微环境,并增强了免疫细胞透.
组合疗法抑制了原发性和转移性瘤生长,减少了复发,并引起了全身抗瘤免疫力.

结论:

TITUR是一个多功能平台,用于瘤学中的向mRNA输送.
这种方法提高了免疫治疗的有效性和安全性,为个性化mRNA纳米药物提供了潜力.
提图尔证明了克服当前免疫疗法的局限性的潜力.

更多相关视频

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes

Published on: November 11, 2016

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.